CERS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 32 of 36 cases where CERS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CERS's RSI Oscillator exited the oversold zone, 25 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for CERS just turned positive on October 20, 2026. Looking at past instances where CERS's MACD turned positive, the stock continued to rise in 35 of 43 cases over the following month. The odds of a continued upward trend are 81%.
Following a +1.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where CERS advanced for three days, in 167 of 224 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 56 cases where CERS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CERS as a result. In 90 of 104 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The 50-day moving average for CERS moved below the 200-day moving average on November 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CERS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for CERS entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.130) is normal, around the industry mean (4.115). P/E Ratio (-71.000) is within average values for comparable stocks, (1.586). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.219) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. CERS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CERS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Stochastic Oscillator for SENS moved out of overbought territory on November 04, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 52 similar instances where the indicator exited the overbought zone. In 47 of the 52 cases the stock moved lower. This puts the odds of a downward move at 90%.
SENS moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SENS crossed bearishly below the 50-day moving average on October 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SENS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
SENS broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SENS entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SENS's RSI Indicator exited the oversold zone, 40 of 46 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on SENS as a result. In 73 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for SENS just turned positive on October 28, 2026. Looking at past instances where SENS's MACD turned positive, the stock continued to rise in 35 of 40 cases over the following month. The odds of a continued upward trend are 88%.
Following a +17.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where SENS advanced for three days, in 198 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. SENS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.678) is normal, around the industry mean (4.115). P/E Ratio (-3.567) is within average values for comparable stocks, (1.586). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (9.058) is also within normal values, averaging (40.124).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SENS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
CERS | SENS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 30 | 66 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 9 Undervalued | 49 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 94 | 99 | |
PRICE GROWTH RATING 1..100 | 44 | 36 | |
P/E GROWTH RATING 1..100 | 14 | 92 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CERS's Valuation (9) in the Medical Specialties industry is somewhat better than the same rating for SENS (49) in the Electronic Components industry. This means that CERS’s stock grew somewhat faster than SENS’s over the last 12 months.
CERS's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as SENS (100) in the Electronic Components industry. This means that CERS’s stock grew similarly to SENS’s over the last 12 months.
CERS's SMR Rating (94) in the Medical Specialties industry is in the same range as SENS (99) in the Electronic Components industry. This means that CERS’s stock grew similarly to SENS’s over the last 12 months.
SENS's Price Growth Rating (36) in the Electronic Components industry is in the same range as CERS (44) in the Medical Specialties industry. This means that SENS’s stock grew similarly to CERS’s over the last 12 months.
CERS's P/E Growth Rating (14) in the Medical Specialties industry is significantly better than the same rating for SENS (92) in the Electronic Components industry. This means that CERS’s stock grew significantly faster than SENS’s over the last 12 months.
| CERS | SENS | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 83% | 1 day ago 87% |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 87% | 1 day ago 86% |
| MACD ODDS (%) | 1 day ago 81% | 1 day ago 88% |
| TrendWeek ODDS (%) | 1 day ago 85% | 1 day ago 86% |
| TrendMonth ODDS (%) | 1 day ago 83% | 1 day ago 85% |
| Advances ODDS (%) | 9 days ago 75% | 9 days ago 81% |
| Declines ODDS (%) | 30 days ago 83% | 4 days ago 85% |
| BollingerBands ODDS (%) | 1 day ago 89% | 1 day ago 81% |
| Aroon ODDS (%) | 1 day ago 87% | 1 day ago 82% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CERS’s FA Score shows that 2 FA rating(s) are green while SENS’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CERS’s TA Score shows that 4 TA indicator(s) are bullish while SENS’s TA Score has 4 bullish TA indicator(s).
CERS (@Medical/Nursing Services) experienced а -12.70% price change this week, while SENS (@Medical/Nursing Services) price change was -18.05% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -6.75%. For the same industry, the average monthly price growth was -8.68%, and the average quarterly price growth was -7.27%.
CERS is expected to report earnings on Feb 25, 2027.
SENS is expected to report earnings on Nov 09, 2026.
The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
A.I.dvisor indicates that over the last year, CERS has been loosely correlated with ICUI. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CERS jumps, then ICUI could also see price increases.
| Ticker / NAME | Correlation To CERS | 1D Price Change % | ||
|---|---|---|---|---|
| CERS | 100% | -11.80% | ||
| ICUI - CERS | 46% Loosely correlated | -2.88% | ||
| UTMD - CERS | 45% Loosely correlated | -1.91% | ||
| RVTY - CERS | 44% Loosely correlated | -5.39% | ||
| ATRC - CERS | 43% Loosely correlated | -6.49% | ||
| DHR - CERS | 43% Loosely correlated | -3.66% | ||
More | ||||
A.I.dvisor indicates that over the last year, SENS has been loosely correlated with RCEL. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if SENS jumps, then RCEL could also see price increases.
| Ticker / NAME | Correlation To SENS | 1D Price Change % | ||
|---|---|---|---|---|
| SENS | 100% | -11.42% | ||
| RCEL - SENS | 42% Loosely correlated | -3.92% | ||
| CERS - SENS | 35% Loosely correlated | -11.80% | ||
| QSI - SENS | 32% Poorly correlated | -9.30% | ||
| VIVO - SENS | 32% Poorly correlated | +20.39% | ||
| MBOT - SENS | 31% Poorly correlated | -6.14% | ||
More | ||||